NCCN has published NCCN Imaging Appropriate Use Criteria for an additional 15 NCCN Clinical Practice Guidelines in Oncology. Launched in June 2016, NCCN Imaging AUC currently are available for 35 NCCN Guidelines. NCCN Imaging AUC are an easy-to-use, single source for AUC pertaining to cancer screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance as...
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
